UK regenerative medical devices company Tissue Regenix Group plc, says it has signed seven independent regional sales distribution agreements in the United States. The regional distributors will actively promote DermaPure™, Tissue Regenix’s dCELL® human dermis into acute care hospitals, Veteran Affairs (VA) Hospitals and institutions as well as Long Term Acute Care hospitals in the US.
Chronic wounds reportedly affect 6.5 million US patients, a market valued at a reported $1.4Billion. This is the focus of Leeds University spin-out Tissue Regenix’s flagship product, DermaPure. DermaPure works by taking human donor skin and removing the DNA and cells, using the patented dCELL® process to leave a natural biological scaffold that can be placed in the wound to aid natural healing by attracting the patient’s own cells to the wound area.
A recently completed trial in the UK by NHS Blood and Transplant (‘NHSBT’) with the University Hospital of South Manchester showed that patients who have had chronic wounds for an average of 4½ years and who were treated with a single application of Tissue Regenix’ DermaPure have seen an 87% reduction in the size of all wounds, while 60% of patients were completely healed, with virtually no recurrences.
Tissue Regenix recently announced a processing agreement partnership with Community Tissue Services (CTS), one of the largest tissue banks in North America, which will result in dCELL® technology now being applied to produce DermaPure for use with acute and chronic wounds.
Tissue Regenix established its USA subsidiary ‘Tissue Regenix Wound Care Inc. in November 2012, as part of its commercialisation strategy for its dCELL® technology platform. In addition to the newly signed distribution agreements the company aims to target all the states within the US, by appointing further distributors, the target being sales coverage exists in all US metropolitan areas by the end 2014.
DermaPure remains on course for its commercial launch in the US during the first three months of 2014.
Greg Bila, President of Tissue Regenix Wound Care Inc. stated; “We are delighted to have signed these seven regional distribution agreements, allowing us to dispense DermaPure to 25 states in the US. These agreements allow us to launch our institutional sales strategy, and we are working hard with the distributors to bring the product to market. With a significant distribution footprint now in place across the US, we remain steadily on course for the North American commercial launch of DermaPure in 2014.”
Source: Tissue Regenix Group plc